Tetrahydrocannabinol

Discovery

Cannabis has been used medicinally for millennia — documented in ancient Vedic texts, Chinese pharmacopoeia, and Egyptian medical papyri.^[11][12] The identity of the psychoactive compound eluded science until 1964, when Yechiel Gaoni and Raphael Mechoulam published the isolation and structural characterization of delta-9-tetrahydrocannabinol.^[1] That single paper founded modern cannabinoid pharmacology.

The endocannabinoid system

THC's isolation set off one of the most productive research programmes in neuroscience. In 1988, a specific cannabinoid binding site was identified in rat brain;^[2] later mapping revealed dense receptor expression in the hippocampus, basal ganglia, cerebellum, and cortex — with sparse brainstem presence, directly explaining why cannabinoids do not suppress breathing.^[8][13] In 1992, the brain's own cannabinoid molecule — anandamide — was isolated, demonstrating that the body runs its own version of this system.^[3]

Clinical development and regulation

Synthetic THC (dronabinol) received FDA approval for chemotherapy-induced nausea in 1985,^[14] and nabiximols (Sativex), a THC:CBD oromucosal spray, was approved in Canada for multiple sclerosis spasticity in 2005.^[15] Cannabis was placed in US Schedule I in 1970;^[16] in April 2026, FDA-approved marijuana products were moved to Schedule III, with broader rescheduling pending.^[4]

Structure and classification

THC belongs to the terpenophenolic structural class — a chemical family characteristic of the phytocannabinoids in Cannabis sativa. It is one of more than 100 phytocannabinoids identified in the plant,^[17] structurally related to cannabidiol (CBD), cannabinol (CBN), and delta-8-THC. Its molecular formula is C₂₁H₃₀O₂ (molecular weight 314.5 g/mol).

Potency and natural occurrence

In the plant, THC exists as its inactive precursor THCA until heat — from smoking, vaporizing, or baking — converts it to the pharmacologically active delta-9-THC.^[17] THC content ranges from less than 0.3% in hemp cultivars to over 25% in high-potency strains^[17] — an 80-fold variation in potency. This matters clinically: daily use of high-potency cannabis (THC ≥10%) is strongly linked to elevated psychotic disorder risk.^[10]

Mechanism of action

THC is a partial agonist at CB1 cannabinoid receptors.^[18] Partial agonism means its maximal effect is lower than synthetic full agonists — its ceiling depends on receptor availability and the brain's existing cannabinoid activity.^[18] The net effect is suppression of neurotransmitter release at synapses throughout the brain, co-opting the retrograde endocannabinoid signalling system.^[19]

Pharmacokinetics

The route of administration determines almost everything about how the experience unfolds.^[9][20] Inhaled THC reaches the bloodstream within minutes, producing effects within seconds;^[9] vaporization achieves higher bioavailability than smoking at equivalent doses.^[21] Oral THC is absorbed poorly (4–20%), with onset delayed 30–90 minutes and peak effects at 2–3 hours — a significant safety risk, as users frequently redose before the first dose has taken full effect.^[9]

Metabolism and elimination

The liver converts THC first to 11-hydroxy-THC (11-OH-THC), an active metabolite that is comparably potent and likely drives much of the oral experience, then to THC-COOH, the inactive compound detected in urine tests.^[20][22] THC accumulates in fat tissue and clears slowly — terminal half-life runs 20–57 hours in occasional users, longer with chronic use.^[9] THC-COOH can remain detectable in urine for days after a single use and weeks to months in heavy users.^[9]

Where it acts

The brain has its own cannabinoid signalling system. Under normal conditions, neurons produce endocannabinoids on demand to briefly dial down activity at neighboring synapses.^[19] THC overrides this by persistently occupying CB1 receptors — imposing sustained suppression of both excitatory and inhibitory signalling, whether needed or not.^[19]

The consequences follow the brain's receptor map^[8]: dense CB1 receptors in the hippocampus produce acute memory suppression;^[6] in the amygdala, modulation creates the biphasic anxiety pattern — low-dose calm, high-dose paranoia;^[5] in the cerebellum and basal ganglia, motor coordination and executive function are impaired.^[23][13]

Why it matters

The endocannabinoid system normally acts as a circuit breaker, preventing runaway excitation or inhibition across neural circuits.^[19] THC disrupts that homeostasis — which is why its effects are so context-dependent. Tolerance builds to cognitive and anxiety effects but not to euphoria^[24]: the reward response persists even as other effects fade, a pattern that drives compulsive use.^[25]

Toxicity

Common acute adverse effects include rapid heartbeat,^[28][6] dizziness from blood pressure drops,^[28] anxiety and panic,^[9][6] and at higher doses, hallucinations, paranoia, and blunted affect.^[6] High-potency cannabis impairs executive function and motor control at common recreational doses.^[23]

Psychological risks

The association between cannabis and psychotic disorder is the most significant psychiatric safety concern. Daily cannabis use carries an odds ratio of 3.2 for psychotic disorder; daily high-potency use (THC ≥10%) raises this to 4.8.^[10] THC is contraindicated in individuals with a personal or family history of psychotic disorders.^[20]

Anxiety is the most common acute adverse psychological effect — low doses may calm, higher doses reliably produce anxiety and panic.^[5] Adolescent cannabis use carries substantially higher psychiatric risk than adult-onset use.^[27][26] Panic attacks are the most frequent adverse reaction prompting emergency department visits.^[9]

Tolerance and dependence

Tolerance develops through CB1 desensitization, beginning within days of heavy regular use and reversing over roughly 2–4 weeks of abstinence.^[34] Tolerance is selective: frequent users become tolerant to cognitive and anxiety-producing effects but not to euphoria.^[24] This preserved reward response, as other effects fade, is significant for dependence risk.

About 9% of cannabis users develop cannabis use disorder, rising to 17% in those who begin in adolescence.^[7] Cannabis withdrawal syndrome affects roughly 50% of regular users upon stopping^[35]: irritability, insomnia, decreased appetite, restlessness, and depressed mood, with physical symptoms (sweating, tremors, abdominal pain) peaking at 2–3 days and resolving within 1–2 weeks.^[34] No FDA-approved medication for cannabis use disorder exists.^[36]

Drug interactions

THC is metabolized primarily by liver enzymes CYP2C9 and CYP3A4. Both THC and CBD inhibit these same enzymes,^[22] raising blood levels of other drugs processed through them — including warfarin, phenytoin, and many common medications. Chronic cannabis users may require higher doses of certain anaesthetics.^[37]

CNS depressants — alcohol, benzodiazepines, opioids, and sedating antihistamines — add to THC's sedation and psychomotor impairment.^[20] Stimulants add to increases in heart rate and blood pressure. THC may reduce the effectiveness of antipsychotics and worsen psychotic symptoms in people with schizophrenia spectrum disorders.

Contraindications

Absolute:

• Active psychotic disorder or personal/family history of psychosis — the psychotomimetic effects^[6] and strong association with psychosis incidence^[10] make this the most critical contraindication.^[20]

• Pregnancy and breastfeeding — THC crosses the placenta and accumulates in breast milk.^[32]

Relative:

• Significant heart conditions — acute increases in heart rate and blood pressure drops may worsen pre-existing cardiac disease.^[20]
• Lung disease — applies to combustion routes; vaporization or oral use may be considered with medical supervision.^[31]
• Active substance use disorder — risk of complicating recovery.^[27]
• Adolescence — elevated risk of lasting cognitive impairment and psychiatric vulnerability.^[26][27]
• Driving or operating machinery while intoxicated — impairment cannot be reliably predicted from blood THC levels.^[33]
• Liver impairment — THC is extensively liver-metabolized; reduced clearance may increase exposure.^[20]

Cannabis and THC occupy one of the most complex and rapidly evolving regulatory landscapes of any psychoactive substance.

The 2018 US Farm Bill exempted hemp (<0.3% Δ9-THC by dry weight) from the Controlled Substances Act, inadvertently creating a regulatory grey area. This led to a proliferation of delta-8-THC and other minor cannabinoid products derived from hemp through chemical conversion. The regulatory status of these semi-synthetic cannabinoids remains contested across jurisdictions.